Pagano L, Tacconelli E, Tumbarello M, Laurenti L, Ortu-La Barbera E, Antinori A, Caponera S, Cauda R, Leone G
Division of Hematology, Università Cattolica del Sacro Cuore, Rome, Italy.
Haematologica. 1997 Jul-Aug;82(4):415-9.
Patients with hematological malignancies are at increased risk for developing bacteremia. No previous study has investigated the risk and prognostic indicators of bacteremia in such patients using a statistical approach.
A case-control study was performed in 106 patients with hematological malignancies (group A). Two hundred and twelve patients were included as controls and divided into two groups: 106 patients with hematological malignancy without bacteremia (group B) and 106 HIV-infected patients with bacteremia (group C).
At univariate analysis, bacteremia risk factors in group A were: neutropenia for more than six days (p = 0.03 vs. group B), central venous catheter usage (p = 0.04) and absence of antibiotic prophylaxis (p = 0.03). At multivariate analysis, the use of CVC and neutropenia were independent bacteremia risk factors. The most frequent etiological agents were: Staphylococcus epidermidis and Pseudomonas aeruginosa. Comparing groups A and C, the distribution of Staphylococcus spp. was different, with S. epidermidis being prevalent in hematological patients only. As regards gram-negative organisms, it is of note that no episode of NT-Salmonella bacteremia was observed in group A, unlike group C, where they represent the second leading etiological agents. In group A, 14% of the patients died. Persistent neutropenia (p = 0.01) and the presence of relapsed neoplasm (p = 0.04) were prognostic indicators of bacteremia.
Our findings suggest that bacteremia in patients with hematological malignancies strictly correlates with the intensity and length of neutropenia and CVC usage. Although we observed a low mortality rate, we stress that this clinical condition requires special attention from the physician, who must recognize and treat it promptly.
血液系统恶性肿瘤患者发生菌血症的风险增加。此前尚无研究采用统计学方法调查此类患者菌血症的风险及预后指标。
对106例血液系统恶性肿瘤患者(A组)进行病例对照研究。纳入212例对照,分为两组:106例无菌血症的血液系统恶性肿瘤患者(B组)和106例感染HIV且有菌血症的患者(C组)。
单因素分析时,A组菌血症的危险因素为:中性粒细胞减少超过6天(与B组相比,p = 0.03)、使用中心静脉导管(p = 0.04)及未进行抗生素预防(p = 0.03)。多因素分析时,使用中心静脉导管和中性粒细胞减少是独立的菌血症危险因素。最常见的病原体为:表皮葡萄球菌和铜绿假单胞菌。比较A组和C组,葡萄球菌属的分布不同,仅在血液系统疾病患者中表皮葡萄球菌占优势。至于革兰阴性菌,值得注意的是,A组未观察到非伤寒沙门菌菌血症发作,而在C组中,它们是第二大主要病原体。A组中14%的患者死亡。持续性中性粒细胞减少(p = 0.01)和肿瘤复发(p = 0.04)是菌血症的预后指标。
我们的研究结果表明,血液系统恶性肿瘤患者的菌血症与中性粒细胞减少的强度和持续时间以及中心静脉导管的使用密切相关。尽管我们观察到死亡率较低,但我们强调这种临床情况需要医生特别关注,医生必须及时识别并进行治疗。